跳至主要内容
临床试验/NCT02457442
NCT02457442已完成4 期

Validation of the Interaction Model of the Anesthetic Potency of Sevoflurane, Propofol and Remifentanil

Insel Gruppe AG, University Hospital Bern1 个研究点 分布在 1 个国家目标入组 172 人开始时间: 2015年12月最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
入组人数
172
试验地点
1
主要终点
20% heart rate or mean arterial pressure increase upon installation of pneumoperitoneum

研究概览

简要总结

Recently a new model for the interaction of sevoflurane propofol and remifentanil was developed. The potency of any combination of the three drugs is defined as probability that a subject tolerates laryngoscopy without movement response. The model allows to compare the potency of intravenous and inhalation anesthetics. If the model is valid also for other stimuli than laryngoscopy and for other responses (e.g. blood pressure or heart rate increase upon stimulation). If the model is valid equipotent concentrations of sevoflurane and propofol the same remifentanil concentration would be sufficient to suppress hemodynamic response to a given stimulus. This will be investigated it the study.

详细描述

Background

In general anesthesia propofol or volatile anesthetic are usually combined with opioids and the synergy between hypnotics and opioids is used to reduce the dose of each component in order to minimize side effects and to allow a rapid recovery. Current pharmacodynamic interaction models allow to estimate the potency of combinations of propofol and opioids, volatile anesthetics and opioids or propofol and sevoflurane respectively. In these interaction models the potency of the drug combinations is expressed as probability that motor response to laryngoscopy is suppressed (= tolerance of laryngoscopy, PTOL). The potency of the hypnotic drugs is represented by the concentration preventing motor response to laryngoscopy in 50% of the population (Ce50 hypnotic). Conversely potency of the opioids is represented as concentration reducing the Ce50 of the hypnotics by 50%.

The data of the three previous studies on propofol-remifentanil, propofol-sevoflurane and sevoflurane-remifentanil interaction were pooled and reanalyzed. The result was a triple interaction model of sevoflurane, propofol and remifentanil where sevoflurane and propofol were additive and either propofol or sevoflurane were synergistic with remifentanil. In contrast to the previous studies the response surface of the propofol-remifentanil and sevoflurane-remifentanil derived from the pooled re-analysis had a similar shape, which is reflected by a common C50 remifentanil and a common slope parameter. This means that remifentanil is equally synergistic to propofol and sevoflurane. The next step is to validate this interaction model with other stimuli than laryngoscopy and with other responses to stimulation that movement.

In clinical practice not motor response but hemodynamic response (heart rate and arterial blood pressure increase) upon surgical stimulation is used to titrate anesthetics and opioids.

In laparoscopic surgery after a small skin incision, carbon dioxide is inflated into the abdominal cavity to maintain an intraabdominal pressure of 14 mmHg. Recently the sevoflurane concentration preventing a heart rate or blood pressure increase greater than 20% upon installation of pneumoperitoneum (MAC BAR pneumoperitoneum) has been determined: The MAC BAR pneumoperitoneum (95% CI) of sevoflurane was 4.6 (4.3-4.9) without opioids and 2.4 (2.2-2.6) and 1.7 (1.4-2.1) vol% with an effect site remifentanil concentration of 1 and 2 ng ml-1.These values all correspond to 90% probability to tolerate laryngoscopy (PTOL) according to our triple interaction model (Hannivoort, BJA 2016), which indirectly supports our model.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ASA physical status 1 or 2
  • Written informed consent
  • Exclusion Criteria
  • Cardiovascular disease
  • Pulmonary disease
  • Liver disease
  • CNS disease
  • Alcohol or drug abuse
  • Chronic intake of CNS active drugs
  • Body mass index > 35
  • Diabetes mellitus
  • Hypersensitivity or allergy to one of the study drugs

排除标准

  • 未提供

研究组 & 干预措施

PR1

Active Comparator

(Arm closed in May 2022) Propofol-Remifentanil: Prop high, Remi low. Changing Remi (up-and-down)

干预措施: Propofol and Remifentanil (Drug)

PR2

Active Comparator

(Arm closed in May 2022) Propofol-Remifentanil: Prop low, Remi high. Changing Prop (up-and-down)

干预措施: Propofol and Remifentanil (Drug)

SR1

Active Comparator

(Arm closed in May 2022) Sevoflurane-Remifentanil: Sevo high, Remi low. Changing Remi (up-and-down)

干预措施: Sevoflurane and Remifentanil (Drug)

SR2

Active Comparator

(Arm closed in May 2022) Sevoflurane-Remifentanil: Sevo low, Remi high. Changing Sevo (up-and-down)

干预措施: Sevoflurane and Remifentanil (Drug)

SPR1

Active Comparator

(Arm closed in October 2023) Sevoflurane-Propofol-Remifentanil: Sevo plus Remi intermediate, Remi intermediate; changing Propofol.

干预措施: SPR 1 (Drug)

SPR2

Active Comparator

(Arm closed in October 2023) Sevoflurane-Propofol-Remifentanil: Sevo plus Remi intermediate, Remi intermediate; changing Sevoflurane.

干预措施: SPR2 (Drug)

结局指标

主要结局

20% heart rate or mean arterial pressure increase upon installation of pneumoperitoneum

时间窗: 5 Minutes upon establishment of intraabdominal working pressure (12 mmHg)

次要结局

  • Postoperative quality of recovery score(During hospital stay, expected to be on average ca. 3-5 days)
  • Mean (SD) Remifentanil concentration during surgery(During surgery, expected to be on average ca. 60 - 240 minutes)
  • Mean (SD) Bloodpressure during surgery(Values recorded on computer HD every 10 sec during anesthesia, expected to be on average ca. 60 - 240 minutes)
  • Mean (SD) Bispectral Index during surgery(Values recorded on computer HD every 10 sec. during anesthesia, expected to be on average ca. 60 - 240 minutes)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验